by Alison Bass | Sep 8, 2011 | conflicts of interest, FDA, health insurers, National Institutes of Health, university industry collaboration
At a time when our own government has stepped back from requiring true transparency about conflicts of interest in medicine, French lawmakers seem to be heading in a much bolder direction. According to Nature Medicine, the French national assembly is considering a...
by Alison Bass | Aug 24, 2011 | conflicts of interest, National Institutes of Health, university industry collaboration
The newly announced rules on financial conflicts of interest among federally funded researchers are certainly an improvement on the existing regulations issued by the National Institutes of Health in 1995 (which were never enforced anyway). But as ethicists and...
by Alison Bass | Aug 3, 2011 | antipsychotic drugs, conflicts of interest, health care costs, university industry collaboration
Medicare and social services for vulnerable Americans are not the only programs on the chopping block with Washington’s deal to raise the debt ceiling and cut trillions of dollars in government spending. Looming ahead may be deep cuts in funding for medical and...
by Alison Bass | Jul 20, 2011 | conflicts of interest, drug marketing, National Institutes of Health, university industry collaboration
I realize this is the dead of summer and every journalist who isn’t on vacation is captivated by the Murdoch phone-hacking scandal. But while everyone is looking the other way, the National Institute of Health’s proposed new rules about the disclosure of...
by Alison Bass | Jul 11, 2011 | antidepressants, conflicts of interest, ghostwriting, scientific misconduct, university industry collaboration
The Project on Government Oversight (POGO) has called on President Obama to remove Amy Gutmann, University of Pennsylvania’s president, as chair of his presidential commission for the study of bioethical issues. The reason: Gutmann did nothing to sanction the...
by Alison Bass | Jul 5, 2011 | antipsychotic drugs, conflicts of interest, pharmaceutical industry, university industry collaboration
Harvard Medical School finally wrapped up its three-year-old investigation of Dr. Joseph Biederman and two colleagues accused of failing to disclose extensive financial conflicts of interest, with essentially a slap on the wrist. In 2008, Congressional investigators...
